Randomized controlled trial of adjunctive Valproate for cognitive remediation in early course schizophrenia

Schizophrenia (SZ) is associated with cognitive impairment that contributes to disability, but the cognitive dysfunction is relatively refractory to pharmacologic intervention. Though Valproate augmentation is reported to improve psychopathology among patients with SZ, its effects on cognitive funct...

Full description

Saved in:
Bibliographic Details
Published in:Journal of psychiatric research 2019-11, Vol.118, p.66-72
Main Authors: Ibrahim, Ibtihal, Tobar, Salwa, Fathi, Warda, ElSayed, Hanan, Yassein, Amal, Eissa, Ahmed, Elsheshtawy, Eman, Elboraei, Hala, Shahda, Mohamed, Elwasify, Mahmoud, Ibrahim, Ahmed, Chen, Kehui, Wood, Joel, Dickerson, Faith, Yolken, Robert H., El Chennawi, Farha, Gur, Raquel, Gur, Ruben, El Bahaey, Wafaa, Nimgaonkar, Vishwajit, Mansour, Hader
Format: Article
Language:English
Subjects:
Cognitive function
Negative symptoms
Schizophrenia
Toxoplasma gondii
Valproate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Schizophrenia (SZ) is associated with cognitive impairment that contributes to disability, but the cognitive dysfunction is relatively refractory to pharmacologic intervention. Though Valproate augmentation is reported to improve psychopathology among patients with SZ, its effects on cognitive functions have not been investigated systematically. Using a randomized double blind placebo controlled design, the effects of Valproate or placebo as adjuncts to risperidone (RISP) treatment were evaluated among patients with early course SZ (N = 109). Domains of cognitive function, estimated using the Arabic version of the Penn Computerized Neurocognitive Battery, were the prime outcomes. Clinical severity and social function were secondary outcomes. We also explored the effects of valproate treatment on serological responses to Toxoplama Gondii (TOXO), a putative risk factor for cognitive dysfunction in SZ. There were no significant differences between Valproate and placebo (PLA) treated groups with respect to changes in cognitive functions, positive or negative symptom scores or daily function scores at the beginning and end of the study. No significant Valproate/PLA differences were noted on TOXO serostatus or TOXO-related cognitive dysfunction. Valproate treatment may not be beneficial for cognitive dysfunction in SZ or for TOXO infection.
ISSN:0022-3956
1879-1379
DOI:10.1016/j.jpsychires.2019.08.011